Journal of the American Academy of Dermatology · 2026
A novel stratification framework based on vascular-fibrotic complications identifies distinct risk endotypes in systemic sclerosis: A retrospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Huidan, Cheng Hao, Li Juanjuan, Zhang Mingyang, Zhao Qiong, Wang Kai, Yan Chenglan, Wen Hongyan
Аннотация
BACKGROUND: Systemic sclerosis (SSc) is highly heterogeneous, and the traditional skin-based classification inadequately guides organ-specific management or predicts prognosis.
OBJECTIVE: To develop and validate a novel stratification framework based on dominant vascular and fibrotic complications to identify distinct risk endotypes.
METHODS: This retrospective cohort study included 281 SSc patients categorized at baseline into 4 subgroups: Vascular-dominant, Fibrotic-dominant, Mixed (both), and Limited (neither). Clinical, serological, and immunophenotypic data were compared. Longitudinal progression was analyzed using Kaplan-Meier and Cox regression.
RESULTS: Four distinct endotypes were identified. The Mixed subgroup (n = 47) was characterized by cytopenias, Th17/Treg imbalance, elevated IL-6, and specific autoantibodies. It demonstrated the shortest median progression-free survival (36 months) and the highest independent risk of disease progression (adjusted hazard ratio = 3.194, 95% confidence interval: 1.219-8.369). Biomarker combinations showed moderate predictive value for subgroup identification.
LIMITATIONS: This single-center study has a moderate sample size, an incomplete biomarker panel, and a relatively short follow-up duration, which may limit generalizability and comprehensive progression assessment.
CONCLUSION: We establish a novel complication-based framework that identifies a high-risk. Mixed vascular-fibrotic endotype, providing a pragmatic tool for early risk stratification and personalized management in SSc.
OBJECTIVE: To develop and validate a novel stratification framework based on dominant vascular and fibrotic complications to identify distinct risk endotypes.
METHODS: This retrospective cohort study included 281 SSc patients categorized at baseline into 4 subgroups: Vascular-dominant, Fibrotic-dominant, Mixed (both), and Limited (neither). Clinical, serological, and immunophenotypic data were compared. Longitudinal progression was analyzed using Kaplan-Meier and Cox regression.
RESULTS: Four distinct endotypes were identified. The Mixed subgroup (n = 47) was characterized by cytopenias, Th17/Treg imbalance, elevated IL-6, and specific autoantibodies. It demonstrated the shortest median progression-free survival (36 months) and the highest independent risk of disease progression (adjusted hazard ratio = 3.194, 95% confidence interval: 1.219-8.369). Biomarker combinations showed moderate predictive value for subgroup identification.
LIMITATIONS: This single-center study has a moderate sample size, an incomplete biomarker panel, and a relatively short follow-up duration, which may limit generalizability and comprehensive progression assessment.
CONCLUSION: We establish a novel complication-based framework that identifies a high-risk. Mixed vascular-fibrotic endotype, providing a pragmatic tool for early risk stratification and personalized management in SSc.